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Abstract
Background:  Approximately 50% of patients with stage 3 Chronic Kidney Disease are 25-
hydroxyvitamin D insufficient, and this prevalence increases with falling glomerular filtration rate.
Vitamin D is now recognised as having pleiotropic roles beyond bone and mineral homeostasis,
with the vitamin D receptor and metabolising machinery identified in multiple tissues. Worryingly,
recent observational data has highlighted an association between hypovitaminosis D and increased
cardiovascular mortality, possibly mediated via vitamin D effects on insulin resistance and
inflammation. The main hypothesis of this study is that oral Vitamin D supplementation will
ameliorate insulin resistance in patients with Chronic Kidney Disease stage 3 when compared to
placebo. Secondary hypotheses will test whether this is associated with decreased inflammation and
bone/adipocyte-endocrine dysregulation.
Methods/Design: This study is a single-centre, double-blinded, randomised, placebo-controlled
trial. Inclusion criteria include; estimated glomerular filtration rate 30-59 ml/min/1.73 m2; aged ≥18
on entry to study; and serum 25-hydroxyvitamin D levels <75 nmol/L. Patients will be randomised
1:1 to receive either oral cholecalciferol 2000IU/day or placebo for 6 months. The primary
outcome will be an improvement in insulin sensitivity, measured by hyperinsulinaemic euglycaemic
clamp. Secondary outcome measures will include serum parathyroid hormone, cytokines
(Interleukin-1β, Interleukin-6, Tumour Necrosis Factor alpha), adiponectin (total and High
Molecular Weight), osteocalcin (carboxylated and under-carboxylated), peripheral blood
mononuclear cell Nuclear Factor Kappa-B p65 binding activity, brachial artery reactivity, aortic
pulse wave velocity and waveform analysis, and indirect calorimetry. All outcome measures will be
performed at baseline and end of study.
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Discussion: To date, no randomised controlled trial has been performed in pre-dialysis CKD
patients to study the correlation between vitamin D status with supplementation, insulin resistance
and markers of adverse cardiovascular risk. We remain hopeful that cholecalciferol may be a safe
intervention, with health benefits beyond those related to bone-mineral homeostasis.
Trial registration: Australian and New Zealand Clinical Trials Registry
ACTRN12609000246280.
Background
Chronic Kidney Disease (CKD) is an independent predic-
tor of all-cause and cardiovascular (CV) mortality[1].
Whilst it is true that traditional Framingham risk factors
are amenable to intervention in CKD, the results of inter-
vention may not be as efficacious as those obtained in the
general population[2,3]. Thus, it has been hypothesised
that there is a unique milieu established in CKD, which
causes excess CV burden by mechanisms that are as yet
not fully understood.
Hypovitaminosis D, measured as circulating 25-hydroxy-
vitamin D (25-OHD), is now widely recognised as a spec-
trum state, incorporating both deficiency (25-OHD <37
nmol/L) and relative insufficiency (38-75 nmol/L)[4].
CKD is an independent risk factor for hypovitaminosis
D3, the prevalence of which negatively correlates with
falling estimated glomerular filtration rate (eGFR) from
CKD stage 3 onwards[5]. To contextualise this, in a recent
audit of our department, the prevalence of hypovitamino-
sis D3 was found to be 54% in patients with CKD stage 3,
with 11% of individuals deficient and 43% insufficient
(unpublished data).
Dobnig et al were amongst the first to demonstrate that
patients in the general population with lower serum 25-
OHD and 1,25-(OH)2D (the active metabolite) at base-
line are at increased risk of all-cause and cardiovascular
mortality[6]. Similar findings have been reported in the
incident haemodialysis population, and in CKD stages 3
and 4[7,8]. Furthermore, observational studies demon-
strate that in End Stage Kidney Disease (ESKD), patients
prescribed active vitamin D compounds appear to have a
26% reduction in mortality, independent of other cardio-
vascular risks, parathyroid hormone (PTH) and bone
mineral markers[9].
There is now emerging mechanistic data from laboratory
studies linking vitamin D to pathological processes that
could explain cardiovascular risk modulation. These
include insulin resistance, inflammation and bone-endo-
crine dysregulation.
Within the CKD population impaired glycaemic control is
highly prevalent[5,10], is associated primarily with an
increase in target tissue insulin resistance[11], and is addi-
tive to the CV burden [12-14]. Insulin sensitivity in nor-
moglycaemic adults has been shown to be improved with
vitamin D supplementation[15], and several small studies
involving haemodialysis patients have yielded similar
results using 1,25-(OH)2D or it's analogues for 4-26
weeks [16-26]. Mechanisms that may explain this
improvement include down-regulation of the Renin-
Angiotensin-Aldosterone system (RAAS), and possibly
up-regulation of the osteocalcin-adiponectin system.
RAAS over-activity is well characterised in vitamin D defi-
ciency[27], although the underlying mechanism for this is
not fully understood. Excessive RAAS activity leads to
diminished activation of the intracellular insulin receptor
substrate-1 (IRS-1) - phosphatidylinositol 3-kinase(PI3-
K) signalling pathway. This ultimately decreases translo-
cation of the GLUT-4 glucose transporters to the cell
membrane in skeletal muscle; a process integral to aug-
ment the action of insulin and enhancing glucose uptake
into cells[27,28].
Osteocalcin is a bone protein secreted by osteoblasts, the
transcription of which is known to be vitamin D respon-
sive[29]. Additionally, osteoblasts express the vitamin D
activating 1α-hydroxylase enzyme (CYP27B1) and ex vivo
culture with the substrate 25-OHD yields greater mRNA
production for osteocalcin than 1,25-(OH)2D, highlight-
ing the possible importance of substrate availability[30].
Recent studies have linked osteocalcin to improved gly-
caemic handling in tissues[31], and osteocalcin knockout
mice exhibit marked insulin resistance and an adverse
metabolic phenotype[32]. High molecular weight
(HMW) adiponectin is an adipokine that is known to
improve glycaemic handling, and negatively correlates
with insulin resistance[33]. Adiponectin release from adi-
pocytes is stimulated by osteocalcin[32] and thus may be
the linking intermediary.
Adverse glycaemic control is also associated with
increased inflammatory stress[34,35], as occurs in CKD,
and the resultant pro-inflammatory state is associated
with atherosclerosis[36,37]. Vitamin D deficiency is asso-
ciated with an increased inflammatory burden in
humans[6], and this can be suppressed using 1,25-
(OH)2D or its analogues, both in vitro and in vivo [38-41].
A major factor affecting cytokine production by circulat-BMC Nephrology 2009, 10:41 http://www.biomedcentral.com/1471-2369/10/41
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ing peripheral blood mononuclear cells (PBMCs) is
Nuclear Factor Kappa-B (NfκB), a family of dimeric
nuclear transcription factors that when activated are asso-
ciated with the production of pro-inflammatory
cytokines. Various groups have shown that the transcrip-
tion factor NFκB family is linked to the vitamin D receptor
(VDR) signalling pathway [42-44], and that vitamin D
inhibits monocyte NFκB p65 activation with down stream
suppression of various pro-inflammatory cytokines
including Tumour Necrosis Factor alpha (TNFα), Inter-
leukin (IL)-1β, and IL-6[45]. PBMCs also possess the
CYP27B1 enzyme[45], which is up-regulated in uraemia
but is not responsive to PTH and calcium like the renal
isoform[46]. This raises the question whether, like osteob-
lasts, there may be more avid responses to supplementing
the substrate precursor 25-OHD. Unfortunately, to date,
Vitamin D intervention trials in the renal literature have
predominantly used active 1,25-(OH)2D compounds and
the results are discrepant, with groups reporting both
decreased and no change in PBMC cytokine production,
with no obvious correlation with serum cytokine profiles,
in either a dose, duration or PBMC specific fashion[41,47-
54].
Whilst active vitamin D3 analogues have limited applica-
tion due to side-effects (hypercalcaemia, hyperphospha-
taemia), vitamin D3 supplementation (as oral
cholecalciferol) is well tolerated at both physiological and
supra-physiological doses, is efficacious at raising 25-
OHD levels, and is not associated with the same degree of
mineral disturbance[55,56].
This study aims to provide prospective data regarding the
novel use of cholecalciferol, a safe and effective vitamin D
supplement, to ameliorate insulin resistance in patients
with CKD. Improvements in insulin sensitivity with
cholecalciferol intervention will be assessed for associa-
tion and possible causation with circulating inflammatory
burden and bone/adipocyte-endocrine regulation. This
will also be related to vascular function, a surrogate
marker for cardiovascular risk.
Methods/Design
This trial is a double-blinded randomised controlled trial.
Informed consent will be obtained from all participants.
The study protocol has received approval from the Prin-
cess Alexandra Hospital Human Research Ethics Commit-
tee (PAH HREC), approval number 2009/097. The project
is funded by a Princess Alexandra Hospital Private Practice
Trust Fund Research Support Grant and a Neorecormon
Research Grant from Roche Products Pty Limited.
Participants
All patients attending the Nephrology outpatient depart-
ment at Princess Alexandra Hospital, Brisbane meeting
inclusion criteria will be invited to participate. Inclusion
criteria include: CKD stage 3 (eGFR[57] 30-59 ml/min/
1.73 m2); age ≥18 or over; and serum 25-hydroxyvitamin
D level <75 nmol/L. Exclusion criteria include: unable or
unwilling to give informed consent; pre-menopausal sta-
tus in females; death or dialysis expected within 6 months;
recipient of a transplant; active (<1 month) inflammatory
or infectious process or use of anti-inflammatory medica-
tion; corticosteroid use (<1 month); oral hypoglycaemic
medication use; current or recent (<3 months) use of drugs
affecting bone turnover, hepatic metabolism of vitamin D,
steroids, or vitamin D containing compounds; malabsorp-
tive state or lactose intolerant; active endocrine disorder
(excluding diabetes); serum corrected calcium >2.54
mmol/L or phosphate >1.49 mmol/L.
Intervention
Randomised patients will receive either 2000IU oral
cholecalciferol/day (two 25 μcg tablets, Ostevit-D, Key
Pharmaceuticals Pty Limited, NSW) or two placebo tab-
lets/day for a total duration of 6 months. Patients with
serum calcidiol levels ≤37 nmol/L cannot be ethically ran-
domised to placebo and will therefore be placed on chole-
calciferol at a dose of 2000IU/day with subsequent follow
up for 6 months. The non-randomised patients will be
analysed primarily by dependent paired sampling, acting
as their own control. If, in subsequent analysis, this group
is found to have comparable baseline characteristics to the
randomised groups, independent analysis will be per-
formed.
Outcomes
All outcome measures will be performed at baseline and
end of study. The primary outcome measure will be a
change in the glucose disposal rate as a marker of insulin
sensitivity as measured by the hyperinsulinaemic eugly-
caemic clamp[58]. Secondary outcome measures will
include serum PTH, cytokines (IL-1β, IL-6, TNFα), adi-
ponectin (total and High Molecular Weight), osteocalcin
(carboxylated and under-carboxylated), and peripheral
blood mononuclear cell NFκB p65 binding activity, all of
which will be tested on -80°C stored serum (nuclear
extract for NFκB) in batch by enzyme-linked immuno-
sorbent assay (ELISA). Brachial artery reactivity, aortic
pulse wave velocity and waveform analysis, and indirect
calorimetry will also be assessed.
Sample size and randomisation
Prospective power calculations based on independent t
testing indicate that the study will have adequate statisti-
cal power (80% probability) to detect a clinically signifi-
cant increase in insulin sensitivity of 12%, assuming α =
0.05 and a population standard deviation of 10%, if 24
patients are recruited in the study (12 in each group).
Using paired t testing for dependent sampling (non-ran-BMC Nephrology 2009, 10:41 http://www.biomedcentral.com/1471-2369/10/41
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domised group, baseline to end of study), 8 patients will
be needed. From previous experience within the renal unit
of CKD trials, it is known that there is a high drop out rate
because of progression to dialysis, death, intercurrent co-
morbidity and loss to follow up. Allowing for a 20% drop
out and using the adjustment factor 1/(1-v)2, a total of 51
patients will need to be recruited.
Randomisation will be by permuted block and stratified
for baseline Body Mass Index (BMI, ≤25 Kg/m2 and >25
Kg/m2) and diabetic status. Randomisation will be per-
formed off-site using a validated Microsoft Access Compu-
ter based system available through the Centre for Clinical
Research Excellence Vascular and Metabolic Health at the
University of Queensland. This will generate a unique
treatment allocation number which will be ascribed to the
patient blindly by the physician. Pharmacy will be un-
blinded and dispense trial medication based upon the
numeric reference prescription, using unmarked bottles,
with generic administration details.
Statistical methods
Data will be assessed for normality of distribution and
transformed as appropriate. The active intervention
(Cholecalciferol) and placebo groups will be compared at
baseline to determine the effectiveness of randomisation.
Euglycaemic clamp data from a healthy, non-uraemic
cohort will be supplied by IH and used for comparison.
Any differences between the groups that may cause poten-
tial confounding (age, sex, ethnicity, BMI, lean:fat mass,
eGFR, calcium, phosphate, PTH, inflammatory markers,
proteinuria) will be assessed and adjusted for in the anal-
ysis by the use of appropriate multivariate techniques.
Statistical analyses will be performed using standard sta-
tistical software (Stata Version 10.0, Texas, USA). For par-
ametric continuous data, results will be expressed as mean
± standard deviation, for non-parametric continuous
data, results will be expressed as median (interquartile
range, IQR), and for categorical data, results will be
expressed as frequencies (percentages %). The degree of
association between 25-hydroxyvitamin D and the varia-
bles of interest will be assessed using Pearson's correlation
for continuous normally distributed variables and Spear-
man's correlation for categorical or non-parametric data.
Linear or binary logistic regression will be performed as
appropriate and standard regression diagnostics will be
performed. Comparison of means for independent sam-
ples will be made using: unpaired t-test (parametric data);
Mann-Whitney test (non-parametric data); and, Fisher's
exact test or Pearson's Chi-square test (categorical data).
Comparisons of means for dependent samples will be by
paired samples t-test (parametric data); Wilcoxon signed
rank test (non-parametric data); and, McNemar's test (cat-
egorical data).
No interim analysis is planned, but patients will be mon-
itored for safety by biochemical testing (serum calcium
and phosphate) at 3 months. Analysis of insulin resist-
ance related to intervention will be by completed cases
only. Secondary hypotheses will be assessed by analysis of
available data and intention to treat.
The hypothesis will be accepted if the null hypothesis can
be rejected at the 0.05 probability level.
Discussion
To date, no randomised controlled trial has been per-
formed in pre-dialysis CKD patients to study the correla-
tion between vitamin D status with supplementation,
insulin resistance and markers of adverse cardiovascular
risk. Given the limitations of active vitamin D com-
pounds, we remain hopeful that cholecalciferol may be a
safer intervention, with health benefits beyond those
related to bone-mineral homeostasis. Ultimately, this trial
will add much needed, controlled, prospective data to the
field, and if positive, lead the way for a larger study
focussed on addressing patient level outcomes in this
challenging population.
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